Who
William P. Forbes
EVP, Chief Development Officer
Company insider
Files Form 4 as: EVP, Chief Development Officer, Heron Therapeutics; Director, Beyond Air; Chief Development Officer, Trevi Therapeutics; President, Medical, R&D & CDO, Salix Pharmaceuticals.
In numbers
- Trades disclosed
- 189
- Buys
- 5
- Sells
- 19
- Bought
- $165K
- Sold
- $16.6M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 13 Jul 2006
- Last trade
- 31 Jul 2026
- Last filed
- 3 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,694 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,694 at $0.00 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,6633,326 at $0.50 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,694 at $0.00 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,694 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,6633,326 at $0.50 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,769 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,6743,348 at $0.50 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,769 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,769 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,769 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,6743,348 at $0.50 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,874 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $5171,101 at $0.47 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,874 at $0.00 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,874 at $0.00 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,874 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $5171,101 at $0.47 | filing |
| 6 Jun 2026filed 8 Jun 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —12,500 | filing |
| 6 Jun 2026filed 8 Jun 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
News
Beyond air power: How long-range missiles are reshaping the rules of warXAIR · indiatimes.com · 19 Oct 2026
0 headlines in the last 90 days name William P. Forbes; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.